Comparison of effectiveness of rifaximin at doses of 1650mg and 2200mg in the treatment of patients with diarrhea-predominant irritable bowel syndrome.

Iran University of Medical Sciences0 个研究点目标入组 150 人开始时间: 待定最近更新: 2023年10月16日

适应症

试验速览

暂无简介。

•Diarrhea-dominant irritable bowel syndrome (IBS-D) patients based on ROME IV criteria
•Patients who are available for the entire study period
•Women and men among Iranian population with more than 16 years old
•Patients who are able to follow the study protocol

•Mild IBS-D (less than 175 points on the IBS-SSS scale)
•All IBD subtypes
•Consumption of Antibiotics or probiotics in the past three months before trial
•A severe concomitant disease (malignancy, hypertension uncontrolled and diabetes mellitus, liver, kidney or heart disorders, serious neurological disorders, psychosis, respiratory disorders such as asthma, chronic obstructive pulmonary disease, hyperthyroidism or hypothyroidism)
•Diagnosed lactose intolerance
•Consumption of motility medications or dietary fiber supplements 2 weeks before the start of the study
•Planning to undergo surgery during the study period
•History of alcohol or drug abuse
•Chronic bowel disorders other than IBS, including inflammatory bowel disease, gastric and duodenal ulcers, celiac disease
•Participation in another clinical trial within the past three months
•Positive PCR result for the COVID-19
•Pregnancy or breastfeeding

发起方